Answers are grounded in this paper and cite their sources.
Combination of abiraterone with androgen deprivation therapy (ADT) has better survival outcomes than ADT alone in metastatic Hormone-sensitive prostate cancer (mHSPC) in the Western population. In this prospective (Clinical Trials Registry-India [CTRI] registered) observational study, we present the comparative oncological outcomes of ADT alone and ADT + abiraterone in Indian patients, which is not available currently.
No takes yet. Share an insight, caveat, or question.
Mandal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: